Krka's strategy for own-brand generic pharmaceutical development is achieved through investment in the research and development capacity and Krka's own production and distribution centres around the world.
The most important result of our major investment activity in the past decade has been the facility for modern solid dosage forms, the Notol plant. The plant has a closed production system with a vertical material flow, high automation, computer management and internal transport. This ensures the highest level of product security and employee protection. Krka's strategy for own-brand generic pharmaceutical development is achieved through investment in research and development capacity and Krka's own production and distribution centres around the world.
The investment in the Sinteza 4 plant supports the vertically integrated production model, which controls the entire process from the development of raw materials and final products. The plant is one of the largest of its kind in Europe, and was constructed in line with the latest technical solutions, GMP and the strictest European standards on health and safety for people and the environment.
The new chemical synthesis plant, which produces APIs for Krka's own-brand products, ensures a complete oversight of the pharmaceutical ingredients that constitute the most important part of medicines.
Krka is now implementing numerous projects for the production of final products and raw materials and the modernisation of infrastructure to provide high-quality support for the business functions of the entire Group.